Effect of a hospital-based case management approach on treatment outcome of patients with tuberculosis

Rong-Luh Lin, Fung-J Lin, Chien-Liang Wu, Ming-Jen Peng, Pei-Jan Chen, Hsu-Tah Kuo, Rong-Luh Lin, Fung-J Lin, Chien-Liang Wu, Ming-Jen Peng, Pei-Jan Chen, Hsu-Tah Kuo

Abstract

Background/purpose: Tuberculosis (TB) continues to pose a heavy public health burden in Taiwan. This prospective study analyzed the factors influencing treatment outcome in patients with TB treated with and without a hospital-based case management (HBCM) approach in a referral center in Taipei.

Methods: A register-based cohort study design was used to enroll all new cases of pulmonary or extrapulmonary TB from February 2003 to January 2004. The case manager served as the coordinator among patients, physicians and public health nurses, to facilitate compliance with anti-TB treatment. Treatment outcomes were assessed according to the consensus recommendations of the World Health Organization and the International Union Against Tuberculosis and Lung Disease.

Results: Suspected or confirmed pulmonary or extrapulmonary TB was diagnosed in 524 patients in our hospital from February 2003 to January 2004. Fifty-two of these patients were excluded due to duplicate reporting, previous treatment or death before enrollment. Out of 472 patients enrolled, 103 whose original diagnosis was revised were further excluded, leaving 369 cases eligible for analysis. Patients with case management had a significantly higher rate of successful treatment (cured plus completed treatment) compared to patients without case management, (240/277, 86.6% vs. 67/92, 72.8%; p = 0.002). The overall successful treatment rate including both case and non-case management was 83.2% (307/369), which was higher than the nationwide surveillance data of 78.3% in 2002 and 69.4% in 2003.

Conclusion: Treatment of TB patients by a HBCM approach provides improved treatment outcomes compared to those without case management.

References

    1. World Health Organization . Global Tuberculosis Control: Surveillance, Planning, Financing. World Health Organization; Geneva, Switzerland: 2004.
    1. World Health Organization An expanded framework for effective tuberculosis control. Int J Tuberc Lung Dis. 2002;6:378–388.
    1. Chaulk CP, Kazandjian VA. Directly observed therapy for treatment completion of pulmonary tuberculosis: consensus statement of the public health tuberculosis guidelines panel. JAMA. 1998;279:943–948.
    1. Caminero JA. Is the DOTS strategy sufficient to achieve tuberculosis control in low- and middle-income countries? Need for interventions in universities and medical schools. Int J Tuberc Lung Dis. 2003;7:509–515.
    1. Chiang CY, Enarson DA, Yang SL. The impact of national health insurance on the notification of tuberculosis in Taiwan. Int J Tuberc Lung Dis. 2002;6:974–979.
    1. Lin RL, Lin FJ, Wu JL, et al., Case management model of tuberculous patients in a metropolitan tertiary center in Taiwan. Annual Meeting of Taiwan Society of Pulmonary and Critical Care Medicine, 2004, Tainan, Taiwan.
    1. Center for Disease Control Taiwan. Communicable Disease Control Act. Department of Health of the Executive Yuan, Taiwan, 2003.
    1. Veen J, Raviglione M, Rieder HL. Standardized tuberculosis treatment outcome monitoring in Europe. Recommendations of a Working Group of the World Health Organization (WHO) and the European Region of the International Union Against Tuberculosis and Lung Disease (IUATLD) for uniform reporting by cohort analysis of treatment outcome in tuberculosis patients. Eur Respir J. 1998;12:505–510.
    1. Center for Disease Control in Taiwan. National Surveillance Network of Communicable Diseases. Available from:
    1. Wu JL, Kuo HT, Huang WC. Evaluation of treatment for pulmonary tuberculosis in Mackay Hospital-analysis of 126 cases. Chin Med J. 1985;35:393–398.
    1. Brewer TF, Heymann SJ. To control and beyond: moving towards eliminating the global tuberculosis threat. J Epidemiol Community Health. 2004;58:822–825.
    1. Behr M, Warren S, Salamon H. Transmission of Mycobacterium tuberculosis from patients smear-negative for acid-fast bacilli. Lancet. 1999;353:444–449.
    1. Zwarenstein M, Schoeman JH, Vundule C. Randomised controlled trial of self-supervised and directly observed treatment of tuberculosis. Lancet. 1998;352:1340–1343.
    1. Walley JD, Khan MA, Newell JN. Effectiveness of the direct observation component of DOTS for tuberculosis: a randomised controlled trial in Pakistan. Lancet. 2001;357:664–669.
    1. Volmink J, Garner P. Directly observed therapy for treating tuberculosis. Cochrane Database Syst Rev. 2005 CD003343.
    1. Mangura B, Napolitano E, Passannante M. Directly observed therapy (DOT) is not the entire answer: an operational cohort analysis. Int J Tuberc Lung Dis. 2002;6:654–661.
    1. Snyder DC, Chin DP. Cost-effectiveness analysis of directly observed therapy for patients with tuberculosis at low risk for treatment default. Am J Respir Crit Care Med. 1999;160:582–586.
    1. Burman WJ, Dalton CB, Cohn DL. A cost-effectiveness analysis of directly observed therapy vs. self-administered therapy for treatment of tuberculosis. Chest. 1997;112:63–70.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir